AAP
FDMT icon

Arax Advisory Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Arax Advisory Partners’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.9K Buy
3,227
+2,959
+1,104% +$28.8K ﹤0.01% 3401
2026
Q1 		$2.5K Sell
268
-185
-41% -$1.61K ﹤0.01% 3041
2025
Q4 		$3.4K Sell
453
-5,585
-92% -$56.7K ﹤0.01% 3044
2025
Q3 		$52.5K Buy
+6,038
New +$36.1K ﹤0.01% 1814
2025
Q2 		– Sell
-628
Closed -$2.03K – 3098
2025
Q1 		$2.03K Buy
+628
New +$2.96K ﹤0.01% 2067

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Arax Advisory Partners's FDMT Position: Q2 2026 in Review

Arax Advisory Partners increased its 4D Molecular Therapeutics (FDMT) stake by 1,104% in Q2 2026, buying an estimated $28.8K and bringing the position to 3,227 shares worth $42.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3401.

Arax Advisory Partners first reported a position in FDMT in Q1 2025 and has held it in 5 quarters since. The position peaked at $52.5K in Q3 2025. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Arax Advisory Partners held 3,227 shares of 4D Molecular Therapeutics worth $42.9K as of Q2 2026.
  • Arax Advisory Partners bought 2,959 4D Molecular Therapeutics shares in Q2 2026, an estimated $28.8K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3401 holding.
  • Arax Advisory Partners first reported a position in 4D Molecular Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Arax Advisory Partners's 4D Molecular Therapeutics position peaked at $52.5K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.